Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Capital Expenditures: 2018-2024

Historic Capital Expenditures for Revolution Medicines (RVMD) over the last 7 years, with Dec 2024 value amounting to $10.3 million.

  • Revolution Medicines' Capital Expenditures fell 4.86% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year increase of 34.06%. This contributed to the annual value of $10.3 million for FY2024, which is 33.37% up from last year.
  • Revolution Medicines' Capital Expenditures amounted to $10.3 million in FY2024, which was up 33.37% from $7.7 million recorded in FY2023.
  • Revolution Medicines' Capital Expenditures' 5-year high stood at $10.8 million during FY2022, with a 5-year trough of $2.9 million in FY2020.
  • For the 3-year period, Revolution Medicines' Capital Expenditures averaged around $9.6 million, with its median value being $10.3 million (2024).
  • Its Capital Expenditures has fluctuated over the past 5 years, first skyrocketed by 122.57% in 2021, then dropped by 28.54% in 2023.
  • Yearly analysis of 5 years shows Revolution Medicines' Capital Expenditures stood at $2.9 million in 2020, then spiked by 122.57% to $6.5 million in 2021, then spiked by 65.69% to $10.8 million in 2022, then dropped by 28.54% to $7.7 million in 2023, then spiked by 33.37% to $10.3 million in 2024.